TY - JOUR
T1 - Adverse drug event-related hospitalisation in persons with neurodevelopmental disorders
T2 - a state-wide retrospective cohort study
AU - Zhou, M.
AU - Du, W.
AU - Salvador-Carulla, L.
AU - Glasgow, N.
N1 - Funding Information:
We thank the NSW Health Department for providing the APDC data. The study sponsors had no further role in the study design, data collection, analyses, interpretation of results, writing of the article or the decision to submit it for publication. We appreciate Prof. Emily Lancsar and reviewers for their constructive advice.
Funding Information:
This study was supported by the NHMRC CREMA Q16 Small Project Grants scheme. M. Z. is supported by the Chinese Scholarship Council affiliated with the Ministry of Education of the P.R. China.
Publisher Copyright:
© 2019 MENCAP and International Association of the Scientific Study of Intellectual and Developmental Disabilities and John Wiley & Sons Ltd
PY - 2019/5
Y1 - 2019/5
N2 - Background: Little is known about the sociodemographic and clinical characteristics of adverse drug events (ADEs) in patients with neurodevelopmental disorders (NDD). Objective: The objective of this study was to describe and compare the demographic details of people with and without NDD hospitalised due to ADEs. Methods: The all-inclusive New South Wales Admitted Patient Data Collection from 2001 to 2014 was employed to identify ADE-related hospitalisations in patients with NDD using the International Classification of Diseases 10th revision Australian modification codes. We derived case sets specific to different clinical groups and patient characteristics and compared proportional differences between patients with and without intellectual disability using chi squared tests. Results: A total of 2173 patients with NDD were admitted for acute care of ADEs, accounting for 0.7% of all ADE-related hospitalisations. Hospitalised ADEs among patients with NDD increased by twofold over the 14-year study period. Psychotropic medications and opioid analgesic medications were leading causes of ADE-related hospitalisations in patients with NDD. Compared with their counterparts, patients with NDD were younger, experienced more socio-economic disadvantage and less private insurance coverage, suffered with less severe but different co-morbid clinical conditions and incurred more challenges in the acute hospital care setting. Conclusion: Although the pattern of ADE-related hospitalisations in patients with NDD differed from that in patients without NDD, there is a lack of targeted healthcare programmes to meet their special needs. This study suggests the need for countermeasures in primary healthcare settings to reduce the burden of ADEs in this vulnerable group.
AB - Background: Little is known about the sociodemographic and clinical characteristics of adverse drug events (ADEs) in patients with neurodevelopmental disorders (NDD). Objective: The objective of this study was to describe and compare the demographic details of people with and without NDD hospitalised due to ADEs. Methods: The all-inclusive New South Wales Admitted Patient Data Collection from 2001 to 2014 was employed to identify ADE-related hospitalisations in patients with NDD using the International Classification of Diseases 10th revision Australian modification codes. We derived case sets specific to different clinical groups and patient characteristics and compared proportional differences between patients with and without intellectual disability using chi squared tests. Results: A total of 2173 patients with NDD were admitted for acute care of ADEs, accounting for 0.7% of all ADE-related hospitalisations. Hospitalised ADEs among patients with NDD increased by twofold over the 14-year study period. Psychotropic medications and opioid analgesic medications were leading causes of ADE-related hospitalisations in patients with NDD. Compared with their counterparts, patients with NDD were younger, experienced more socio-economic disadvantage and less private insurance coverage, suffered with less severe but different co-morbid clinical conditions and incurred more challenges in the acute hospital care setting. Conclusion: Although the pattern of ADE-related hospitalisations in patients with NDD differed from that in patients without NDD, there is a lack of targeted healthcare programmes to meet their special needs. This study suggests the need for countermeasures in primary healthcare settings to reduce the burden of ADEs in this vulnerable group.
KW - adverse drug events
KW - hospital care
KW - neurodevelopmental disorders
KW - therapeutic medications
UR - http://www.scopus.com/inward/record.url?scp=85059527903&partnerID=8YFLogxK
U2 - 10.1111/jir.12586
DO - 10.1111/jir.12586
M3 - Article
C2 - 30609156
AN - SCOPUS:85059527903
SN - 0964-2633
VL - 63
SP - 429
EP - 440
JO - Journal of Intellectual Disability Research
JF - Journal of Intellectual Disability Research
IS - 5
ER -
